ArticleScientific reports2026
LncRNA FOXP4-AS1 facilitates colorectal cancer invasion and migration by enhancing USP7 interaction with ZEB1.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Colorectal cancer (CRC) poses a threat to the health of people worldwide. Long noncoding RNAs (lncRNAs) have been reported to play a key role in regulating carcinogenesis, including CRC. In this study, the levels of lncRNA FOXP4-AS1 were analyzed in CRC specimens and cells via qRT-PCR. The impacts of FOXP4-AS1 on CRC cell metastasis were investigated. Then, the silver staining assay, western blot, RIP, Co-IP, and immunofluorescence were conducted to explore and validate the molecular mechanisms by which FOXP4-AS1 affects CRC progression. We discovered that FOXP4-AS1 expression was markedly elevated in CRC. Functionally, FOXP4-AS1 knockdown suppressed CRC cell migration, invasion, and EMT. Also, FOXP4-AS1 silencing weakened CRC tumor growth in vivo. Mechanistically, we identified that FOXP4-AS1 functioned as a scaffold to simultaneously bind USP7 and ZEB1, and regulated the ubiquitination and expression of ZEB1 by binding to USP7. Rescue experiments demonstrated that USP7 inhibitor P005091 abolished the promotion of cell metastasis by FOXP4-AS1 overexpression. Furthermore, ZEB1 overexpression reversed the impact of silencing FOXP4-AS1 on cell metastasis. Collectively, our work revealed the molecular mechanism and role of FOXP4-AS1-mediated USP7-ZEB1 axis in CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.